Comprehensive Guide to Vericiguat: Uses, Dosage, Side Effects, and More
What is Vericiguat?
Overview of Vericiguat
Generic Name: Vericiguat
Brand Name: Verquvo, generics
Drug Group: Soluble guanylate cyclase stimulator (cardiovascular)
Commonly Used For
This medication is used to:
- Reduce heart failure hospitalization risk.
- Improve outcomes in HFrEF.
- Enhance cardiac function in chronic heart failure.
Key Characteristics
- Form: Oral tablets (2.5 mg, 5 mg, 10 mg) (detailed in Dosage section).
- Mechanism: Stimulates sGC, increasing cGMP to promote vasodilation and reduce cardiac stress.
- Approval: FDA-approved (2021 for Verquvo) and EMA-approved for HFrEF.
Indications and Uses of Vericiguat
Vericiguat is indicated for cardiovascular conditions, leveraging its sGC-stimulating effects to improve heart failure outcomes:
Heart Failure with Reduced Ejection Fraction (HFrEF): Reduces the risk of cardiovascular death and hospitalization in adults with HFrEF (LVEF ≤45%) following a worsening event, supported by the VICTORIA trial, per cardiology guidelines.
Chronic Heart Failure Management: Enhances symptom control and quality of life in stable HFrEF patients, used as an adjunct to standard therapy (e.g., ACE inhibitors, beta-blockers).
Post-Myocardial Infarction Heart Failure: Investigated off-label to manage HFrEF after myocardial infarction, reducing remodeling and improving ejection fraction, with emerging cardiology data.
Pulmonary Hypertension Associated with Heart Failure: Explored off-label for Group 2 pulmonary hypertension in HFrEF, alleviating right heart strain, supported by pulmonary hypertension studies.
Diastolic Heart Failure (HFpEF): Used off-label in heart failure with preserved ejection fraction to improve diastolic function, with preliminary evidence from cardiovascular research.
Cardiomyopathy: Employed off-label in non-ischemic cardiomyopathy to reduce hospitalizations, enhancing long-term prognosis, noted in heart failure cohorts.
Post-Cardiac Surgery Recovery: Investigated off-label to support cardiac recovery after coronary artery bypass grafting or valve surgery, improving hemodynamics, with surgical cardiology insights.
Renal Dysfunction in Heart Failure: Explored off-label to mitigate cardiorenal syndrome in HFrEF patients, preserving kidney function, supported by nephrology and cardiology studies.
Hypertensive Heart Disease: Used off-label to manage heart failure symptoms in patients with uncontrolled hypertension, reducing left ventricular hypertrophy, with hypertension research data.
Dosage of Vericiguat
Dosage for Adults
HFrEF (Initial): Start with 2.5 mg once daily, taken with food, for 2 weeks.
Titration: Increase to 5 mg once daily for 2 weeks, then to 10 mg once daily if tolerated, maximum 10 mg/day.
Maintenance: 10 mg once daily, adjusted for hypotension or side effects.
Dosage for Children
Not Approved: Not recommended for pediatric use due to lack of safety and efficacy data.
Dosage for Pregnant Women
Pregnancy Category N (Not Classified): Limited data; use only if benefits outweigh risks. Consult an obstetrician, with fetal monitoring.
Dosage Adjustments
Renal Impairment: No adjustment needed; monitor in severe cases (eGFR <15 mL/min/1.73 m²).
Hepatic Impairment: Mild (Child-Pugh A): No adjustment; moderate (Child-Pugh B): Use caution; severe (Child-Pugh C): Avoid.
Elderly: Start with 2.5 mg once daily; titrate slowly to 10 mg if tolerated.
Concomitant Medications: Adjust if combined with nitrates or PDE-5 inhibitors, increasing hypotension risk.
Additional Considerations
- Take this active ingredient with food to improve absorption and reduce gastric irritation.
- Monitor blood pressure regularly during titration.
How to Use Vericiguat
Administration:
- Swallow tablets whole with a meal or snack, using water; avoid crushing or splitting.
- Take at the same time daily, preferably with breakfast, for consistency.
Timing: Use once daily, with gradual titration over weeks as directed.
Monitoring: Watch for dizziness, lightheadedness, or signs of hypotension (e.g., fainting).
Additional Tips:
- Store at 20–25°C (68–77°F), protecting from moisture and heat.
- Keep out of reach of children due to overdose risk.
- Report severe fatigue, swelling, or signs of allergic reaction immediately.
Contraindications for Vericiguat
Hypersensitivity: Patients with a known allergy to Vericiguat or sGC stimulators.
Concomitant Use with Nitrates: Avoid due to severe hypotension risk.
Severe Hepatic Impairment: Contraindicated in Child-Pugh Class C.
Severe Renal Impairment: Avoid if eGFR <15 mL/min/1.73 m².
Warnings & Precautions for Vericiguat
General Warnings
Hypotension: Risk of symptomatic hypotension, especially during initiation; monitor blood pressure.
Anemia: May reduce hemoglobin levels; check blood counts regularly.
Worsening Heart Failure: Risk if titrated too quickly; adjust dose cautiously.
Syncope: Potential for fainting in volume-depleted patients; ensure hydration.
Drug Interactions: Enhanced effects with PDE-5 inhibitors; avoid combinations.
Additional Warnings
Renal Dysfunction: Risk of worsening kidney function in advanced CKD; monitor eGFR.
Electrolyte Imbalance: Potential hypokalemia or hyperkalemia; assess electrolytes.
Cardiovascular Events: Rare risk of atrial fibrillation; monitor ECG if symptomatic.
Liver Injury: Mild elevation of liver enzymes; monitor in chronic use.
Hypersensitivity Reactions: Rare anaphylaxis; discontinue if swelling occurs.
Use in Specific Populations
Pregnancy: Category N; avoid unless critical; use alternatives if possible.
Breastfeeding: Excreted in breast milk; monitor infant for effects.
Elderly: Higher risk of hypotension; start with lower doses.
Children: Not approved; avoid use.
Renal/Hepatic Impairment: Adjust dose; avoid in severe cases.
Additional Precautions
- Inform your doctor about kidney disease, low blood pressure, or medication history before starting this medication.
- Avoid abrupt cessation; taper if discontinuing long-term therapy.
Overdose and Management of Vericiguat
Overdose Symptoms
- Dizziness, hypotension, or syncope.
- Severe cases: Acute kidney injury, shock, or cardiac arrest.
- Fatigue, nausea, or headache as early signs.
- Respiratory distress with extremely high doses.
Immediate Actions
Contact the Medical Team: Seek immediate medical help.
Supportive Care: Administer IV fluids, monitor vital signs, and correct hypotension with vasopressors if needed.
Specific Treatment: No antidote; manage symptoms and stabilize hemodynamics.
Monitor: Check blood pressure, kidney function, and oxygen saturation for 24–48 hours.
Additional Notes
- Overdose risk is moderate; store securely.
- Report persistent symptoms (e.g., severe weakness, confusion) promptly.
Side Effects of Vericiguat
Common Side Effects
- Hypotension (10–15%, manageable with hydration)
- Anemia (7–12%, monitored with blood tests)
- Headache (5–10%, relieved with rest)
- Nausea (4–8%, reduced with food)
- Dizziness (3–7%, decreases with tolerance)
These effects may subside with dose adjustment.
Serious Side Effects
Seek immediate medical attention for:
- Cardiovascular: Severe hypotension, syncope, or shock.
- Hematologic: Significant anemia or bleeding.
- Renal: Acute kidney injury or oliguria.
- Hepatic: Jaundice or liver failure.
- Allergic: Rash, angioedema, or anaphylaxis.
Additional Notes
- Regular monitoring for blood pressure, hemoglobin, and kidney function is advised.
- Report any unusual symptoms (e.g., fainting, yellow skin) immediately to a healthcare provider.
Drug Interactions with Vericiguat
This active ingredient may interact with:
- Nitrates: Increases hypotension risk; avoid.
- PDE-5 Inhibitors: Enhances vasodilatory effects (e.g., sildenafil); avoid.
- Antihypertensives: Potentiates blood pressure reduction; monitor closely.
- CYP Inhibitors/Inducers: Minimal effect; monitor if combined with strong CYP3A4 agents.
- Diuretics: Increases dehydration risk; adjust dose.
Action: Provide your healthcare provider with a complete list of medications.
Patient Education or Lifestyle
Medication Adherence: Take this sGC stimulator as prescribed to manage heart failure, following the exact titration schedule.
Monitoring: Report dizziness, swelling, or fatigue immediately.
Lifestyle: Avoid dehydration; limit alcohol intake.
Diet: Take with food; maintain a low-sodium diet to support heart health.
Emergency Awareness: Know signs of hypotension or kidney issues; seek care if present.
Follow-Up: Schedule regular check-ups every 1–3 months to monitor blood pressure, kidney function, and heart status.
Pharmacokinetics of Vericiguat
Absorption: Well-absorbed orally (peak at 1–4 hours); enhanced with food.
Distribution: Volume of distribution ~44 L; 98% protein-bound.
Metabolism: Hepatic via glucuronidation (UGT1A1, UGT1A9) to inactive metabolites.
Excretion: Primarily renal (53%) as metabolites; fecal (45%); half-life 20–32 hours.
Half-Life: 20–32 hours, with sustained cardiovascular effects.
Pharmacodynamics of Vericiguat
This drug exerts its effects by:
Stimulating sGC independently of NO levels, enhancing cGMP production.
Promoting vasodilation, reducing preload and afterload in HFrEF.
Improving myocardial energetics and preventing adverse remodeling.
Exhibiting dose-dependent risks of hypotension and anemia.
Storage of Vericiguat
Temperature: Store at 20–25°C (68–77°F); protect from moisture.
Protection: Keep in original container, away from light.
Safety: Store out of reach of children due to overdose risk.
Disposal: Dispose of unused tablets per local regulations or consult a pharmacist.
Frequently Asked Questions (FAQs)
Q: What does Vericiguat treat?
A: This medication treats heart failure with reduced ejection fraction.
Q: Can this active ingredient cause dizziness?
A: Yes, dizziness may occur; stay hydrated.
Q: Is Vericiguat safe for children?
A: No, it’s not approved for pediatric use.
Q: How is this drug taken?
A: Orally as tablets once daily with food, as directed.
Q: How long is Vericiguat treatment?
A: Long-term for chronic heart failure management.
Q: Can I use Vericiguat if pregnant?
A: Yes, with caution; consult a doctor.
Regulatory Information
This medication is approved by:
- U.S. Food and Drug Administration (FDA): Approved in 2021 (Verquvo) for HFrEF.
- European Medicines Agency (EMA): Approved for HFrEF management.
- Other Agencies: Approved globally for heart failure; consult local guidelines.
References
- U.S. Food and Drug Administration (FDA). (2023). Verquvo (Vericiguat) Prescribing Information.
- Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
- European Medicines Agency (EMA). (2023). Vericiguat Summary of Product Characteristics.
- EMA’s comprehensive information on the medication’s indications and precautions in Europe.
- National Institutes of Health (NIH). (2023). Vericiguat: MedlinePlus Drug Information.
- NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
- World Health Organization (WHO). (2023). WHO Guidelines on Cardiovascular Diseases: Vericiguat.
- WHO’s recommendations for Vericiguat in heart failure care.
- New England Journal of Medicine. (2021). Vericiguat in Heart Failure.
- Peer-reviewed article on Vericiguat efficacy from the VICTORIA trial (note: access may require a subscription).
